Research programme: metabolic disorders therapy - Metabolex/Takeda
Latest Information Update: 20 Dec 2013
At a glance
- Originator Metabolex; Takeda
- Developer CymaBay Therapeutics; Takeda
- Class Antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 10 Dec 2013 Discontinued for Metabolic disorders in USA (unspecified route)
- 15 Apr 2010 Early research in Metabolic disorders in USA (unspecified route)